Purple Biotech Ltd. American Depositary Shares (PPBT) is a publicly traded Healthcare sector company. As of May 21, 2026, PPBT trades at $2.79 with a market cap of $3.51M and a P/E ratio of 0.00. PPBT moved -11.11% today. Year to date, PPBT is -57.03%; over the trailing twelve months it is -87.63%. Its 52-week range spans $2.71 to $139.50. Analyst consensus is buy with an average price target of $30.00. Rallies surfaces PPBT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Purple Biotech’s IM1240 Shows Potent Activity in Resistant Tumors, Cash Runway Into 2027: New IM1240 tri-specific antibody data showed potent killing across all treatment-resistant patient-derived tumor samples and improved therapeutic index thanks to the NKG2A arm. Purple Biotech held $6.4 million cash at March 31, 2026, securing runway into 2027 and established a CAPTN-3 Scientific Advisory Board plus a generative AI collaboration.
| Metric | Value |
|---|---|
| Price | $2.79 |
| Market Cap | $3.51M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $139.50 |
| 52-Week Low | $2.71 |
| Volume | 19.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover PPBT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.00.